Pembrolizumab + Axatilimab
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TNBC - Triple-Negative Breast Cancer
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trial Timeline
Nov 17, 2023 → Dec 1, 2026
NCT ID
NCT05491226About Pembrolizumab + Axatilimab
Pembrolizumab + Axatilimab is a phase 2 stage product being developed by Merck for TNBC - Triple-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05491226. Target conditions include TNBC - Triple-Negative Breast Cancer, Breast Cancer.
What happened to similar drugs?
0 of 2 similar drugs in TNBC - Triple-Negative Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015853 | Phase 2 | Recruiting |
| NCT05491226 | Phase 2 | Active |
Competing Products
14 competing products in TNBC - Triple-Negative Breast Cancer